Answers are grounded in this paper and cite their sources.
Objective physical activity monitoring via physical activity monitors (PAMs) is increasingly utilized as a continuous outcome measure in canine osteoarthritis (OA) trials [1]. However, its sensitivity to therapeutic response in dogs presenting with predominant single-limb lameness remains poorly defined. In this secondary analysis of a randomized, double-blind noninferiority trial, we evaluated weekday 24-hour physical activity profiles in 33 client-owned dogs with hip and/or stifle OA and predominant single-limb lameness treated with bedinvetmab or grapiprant. Collar-mounted Actical accelerometers recorded continuous activity in 1-minute epochs over 5 consecutive weekdays preceding Day 0 (baseline) and Day 42. Functional mixed-effects models were fitted to hourly aggregated, log-transformed activity profiles to test for population-level changes and evaluate individual response heterogeneity. Despite improvements in index-limb peak vertical force and owner-reported outcomes in the parent trial, functional data analysis revealed no population-level difference in weekday activity profiles between baseline and Day 42. These findings demonstrate that effective alleviation of single-limb OA pain—evidenced by improved limb loading—does not necessarily translate to increased daily physical activity. This should not be interpreted as ineffective analgesia but instead highlights the importance of selecting outcome measures suited to the phenotype and functional domain impaired at baseline.
No takes yet. Share an insight, caveat, or question.
McMahon et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: